research use only

Lupeol Immunology & Inflammation related chemical

Name: Lupeol
Brand: Selleck Chemicals
SKU: S3614
Availability: InStock
Rating: 5 (5 reviews)

Cat.No.S3614

Lupeol (Clerodol, Monogynol B, Fagarasterol, Farganasterol) is a significant lupane-type triterpene represented in the plant, fungi and animal kingdoms with anticancer, antiprotozoal, chemopreventive and anti-inflammatory properties.

Chemical Structure

Molecular Weight: 426.72

Jump to

Quality Control

Batch: Purity: 100.00%

100.00

Related Targets	PD-1/PD-L1 CXCR STING AhR CD markers Interleukins Anti-infection Antioxidant COX Histamine Receptor
Other Immunology & Inflammation related Inhibitors	Cl-amidine Bestatin (Ubenimex) Bindarit (AF 2838) Tempol Tranilast Sinomenine GI254023X (GI4023) Geniposidic acid CORM-3 Germacrone

Solubility

In vitro
Batch:

DMSO : 3 mg/mL (7.03 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.150mg/ml (0.35mM)	Taking the 1 mL working solution as an example, add 50 μL of 3 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.150mg/ml (0.35mM)	Taking the 1 mL working solution as an example, add 50 μL of 3 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	426.72	Formula	C₃₀H₅₀O	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	545-47-1	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	(3β,13ξ)-Lup-20(29)-en-3-ol, Clerodol, Monogynol B, Fagarasterol, Farganasterol			Smiles	CC(=C)C1CCC2(C1C3CCC4C5(CCC(C(C5CCC4(C3(CC2)C)C)(C)C)O)C)C

Mechanism of Action

In vitro	Lupeol is a multi-target agent with immense anti-inflammatory potential targeting key molecular pathways which involve nuclear factor kappa B (NFκB), cFLIP, Fas, Kras, phosphatidylinositol-3-kinase (PI3K)/Akt and Wnt/β-catenin in a variety of cells. This compound can induce apoptosis of human promyelotic HL-60 leukemia cells and induce the formation of hypodiploid nuclei and fragmentation of DNA in a dose and time dependent manner. It induces death of cancer cell lines of various histopathological origins, including T-lymphoblastic leukemia CEM (IC50 = 50 μM), breast carcinoma MCF-7 (IC50 = 50 μM), lung carcinoma A-549 (IC50 = 50 μM), multiple myeloma RPMI 8226 (IC50 = 50 μM), cervical carcinoma HeLa (IC50 = 37 μM), and malignant melanoma G361 (IC50 = 50 μM) when treated for 72 h. This agent also inhibits the proliferation of the ERα-negative breast cancer cells MDA-MB-231. This chemical (50-30 μg/ml) exhibits anti-angiogenic property in an in vitro tube formation model of human umbilical venous endothelial cells. It inhibits the PI3K/Akt, NFκB signaling network, and decreases the activity of Ras protein (GTP-bound Ras) in pancreatic cancer cells. The compound modulates the microtubule assembly and the protein level of its regulatory molecules such as Stathmin and Survivin in prostate cancer cells thus causing G2/M cell cycle arrest. It has been shown to act as a potent inhibitor of protein kinases and serine proteases and inhibit the activity of DNA topoisomerase II, a target for anticancer chemotherapy.
In vivo	Topical application of Lupeol decreases myeloperoxidase levels thus causing reduction in cell infiltration into inflamed tissues in mice. Oral administration of this compound (12.5-200 mg/kg) results in the significant reduction in CD4+ T and CD8+ T cell counts and the level of cytokines (IL-2, IFN-gamma and IL-4) in arthritic mice. Its administration causes a significant reduction in cellularity and eosinophil levels in the broncho-alveolar fluid. It also exerts its wound healing effect by decreasing the level of monocytes and docking with GSK3β protein. For cancer, this agent significantly inhibits the NFκB translocation and its DNA binding activity in a mouse model of skin tumorigenesis. It inhibits growth of highly metastatic tumors of human melanoma origin by modulating ratio of Bcl-2 and Bax protein levels in vitro and in vivo. Thus, this compound itself being non-toxic to normal cells could be used as a chemopreventive as well chemotherapeutic agent against skin cancer. It has been shown to inhibit the generation of ROS and restore the depleted antioxidant levels within prostatic tissue of androgen pretreated mice. This chemical is a non-toxic but highly potent chemopreventive and chemotherapeutic agent.
References	[1] https://pubmed.ncbi.nlm.nih.gov/19464787/ [2] https://pubmed.ncbi.nlm.nih.gov/15122342/ [3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722146/

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):